{"nctId":"NCT01422876","briefTitle":"Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients","startDateStruct":{"date":"2011-08"},"conditions":["Diabetes Mellitus, Type 2"],"count":1405,"armGroups":[{"label":"BI 10773/linagliptin FDC (high dose)","type":"EXPERIMENTAL","interventionNames":["Drug: high dose FDC","Drug: low dose FDC placebo","Drug: high dose BI 10773 placebo","Drug: BI 10773 low dose placebo","Drug: linagliptin placebo"]},{"label":"BI 10773/linagliptin FDC (low dose)","type":"EXPERIMENTAL","interventionNames":["Drug: high dose FDC placebo","Drug: low dose FDC","Drug: high dose BI 10773 placebo","Drug: BI 10773 low dose placebo","Drug: linagliptin placebo"]},{"label":"BI 10773 (high dose)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BI 10773 high dose","Drug: high dose FDC placebo","Drug: low dose FDC placebo","Drug: low dose BI 10773 placebo","Drug: linagliptin placebo"]},{"label":"BI 10773 (low dose)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: high dose FDC placebo","Drug: low dose FDC placebo","Drug: high dose BI 10773 placebo","Drug: BI 10773 low dose","Drug: linagliptin placebo"]},{"label":"Linagliptin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: low dose FDC placebo","Drug: high dose FDC placebo","Drug: linagliptin","Drug: high dose BI 10773 placebo","Drug: low dose BI 10773 placebo"]}],"interventions":[{"name":"high dose FDC","otherNames":[]},{"name":"BI 10773 high dose","otherNames":[]},{"name":"high dose FDC placebo","otherNames":[]},{"name":"low dose FDC placebo","otherNames":[]},{"name":"high dose FDC placebo","otherNames":[]},{"name":"high dose FDC placebo","otherNames":[]},{"name":"low dose FDC placebo","otherNames":[]},{"name":"low dose FDC placebo","otherNames":[]},{"name":"high dose BI 10773 placebo","otherNames":[]},{"name":"low dose FDC","otherNames":[]},{"name":"high dose FDC placebo","otherNames":[]},{"name":"BI 10773 low dose","otherNames":[]},{"name":"high dose BI 10773 placebo","otherNames":[]},{"name":"high dose BI 10773 placebo","otherNames":[]},{"name":"linagliptin","otherNames":[]},{"name":"low dose FDC placebo","otherNames":[]},{"name":"linagliptin placebo","otherNames":[]},{"name":"BI 10773 low dose placebo","otherNames":[]},{"name":"linagliptin placebo","otherNames":[]},{"name":"low dose BI 10773 placebo","otherNames":[]},{"name":"linagliptin placebo","otherNames":[]},{"name":"high dose BI 10773 placebo","otherNames":[]},{"name":"BI 10773 low dose placebo","otherNames":[]},{"name":"low dose BI 10773 placebo","otherNames":[]},{"name":"linagliptin placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Diagnosis of type 2 diabetes mellitus prior to informed consent\n2. Male and female patients on diet and exercise regimen who are drug-naïve (defined as absence of any oral antidiabetic therapy, glucagon like peptide-1 analog or insulin for 12 weeks prior to randomization) or pre-treated with metformin (=1500 mg/day or on the maximum tolerated dose or the maximum dose according to local label) unchanged for 12 weeks prior to randomisation.\n3. Glycosylated hemoglobin (HbA1c) = 7.0% and = 10.5% (= 53.0 mmol/mol and = 91.3 mmol/mol) at Visit 1 (screening)\n\nExclusion criteria:\n\n1. Uncontrolled hyperglycemia with a glucose level \\>240 mg/dl (\\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day).\n2. Any other antidiabetic drug within 12 weeks prior to randomization (except metformin background therapy as defined via inclusion criterion 2)\n3. Acute coronary syndrome (non-ST elevation myocardial infarction, ST elevation myocardial infarction and unstable angina pectoris), stroke or (transient ischemic attack) TIA within 3 months prior to informed consent","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients","description":"Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.19","spread":"0.06"},{"groupId":"OG001","value":"-1.08","spread":"0.06"},{"groupId":"OG002","value":"-0.62","spread":"0.06"},{"groupId":"OG003","value":"-0.66","spread":"0.06"},{"groupId":"OG004","value":"-0.70","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 24 for Metformin Background Patients","description":"Change from baseline in fasting plasma glucose at week 24 for Metformin Background patients.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.25","spread":"2.53"},{"groupId":"OG001","value":"-32.18","spread":"2.52"},{"groupId":"OG002","value":"-18.83","spread":"2.47"},{"groupId":"OG003","value":"-20.84","spread":"2.50"},{"groupId":"OG004","value":"-13.05","spread":"2.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 24 for Treatment Naive Patients","description":"Change from baseline in fasting plasma glucose at week 24 for Treatment Naive patients.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-29.55","spread":"2.67"},{"groupId":"OG001","value":"-28.21","spread":"2.66"},{"groupId":"OG002","value":"-24.24","spread":"2.68"},{"groupId":"OG003","value":"-22.39","spread":"2.69"},{"groupId":"OG004","value":"-5.92","spread":"2.68"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight for Metformin Background Patients","description":"Change from baseline in body weight for Metformin Background patients.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.99","spread":"0.31"},{"groupId":"OG001","value":"-2.60","spread":"0.30"},{"groupId":"OG002","value":"-3.18","spread":"0.30"},{"groupId":"OG003","value":"-2.53","spread":"0.30"},{"groupId":"OG004","value":"-0.69","spread":"0.31"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Treatment Naive Patients","description":"Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"0.07"},{"groupId":"OG001","value":"-1.24","spread":"0.07"},{"groupId":"OG002","value":"-0.95","spread":"0.07"},{"groupId":"OG003","value":"-0.83","spread":"0.07"},{"groupId":"OG004","value":"-0.67","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight for Treatment Naive Patients","description":"Change from baseline in body weight for Treatment Naive patients.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.00","spread":"0.36"},{"groupId":"OG001","value":"-2.74","spread":"0.36"},{"groupId":"OG002","value":"-2.13","spread":"0.36"},{"groupId":"OG003","value":"-2.27","spread":"0.37"},{"groupId":"OG004","value":"-0.78","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Occurrence of Treat to Target Efficacy Response for Metformin Background Patients","description":"Occurrence of the treat-to-target efficacy response for Metformin Background patients measured as HbA1c \\< 7.0% after 24 weeks of treatment for patients with HbA1c \\>=7.0% at baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.8","spread":null},{"groupId":"OG001","value":"57.8","spread":null},{"groupId":"OG002","value":"32.6","spread":null},{"groupId":"OG003","value":"28.0","spread":null},{"groupId":"OG004","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence of Treat to Target Efficacy Response for Treatment Naive Patients","description":"Occurrence of the treat-to-target efficacy response for Treatment Naive patients measured as HbA1c \\< 7.0% after 24 weeks of treatment for patients with HbA1c \\>=7.0% at baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.4","spread":null},{"groupId":"OG001","value":"62.3","spread":null},{"groupId":"OG002","value":"41.5","spread":null},{"groupId":"OG003","value":"38.8","spread":null},{"groupId":"OG004","value":"32.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":273},"commonTop":["Urinary tract infection","Headache","Upper respiratory tract infection","Nasopharyngitis","Hyperglycaemia"]}}}